Marker Therapeutics is trading at $1.33, up 8.99% in pre-market after highlighting expanded manufacturing support for its MT-601 program; direct causation is unconfirmed.
- Manufacturing partner Cellipont Bioservices combined with Kincell Bio to form Kincellis Advanced Therapies, with approximately 140,000 square feet, 16 GMP suites and three U.S. locations.
- The company announcement was published September 22; shares closed at $1.22 that day after several modest gains. Broader biotech strength may also support sentiment.